Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
genetic disorder
|
| gptkbp:advertising |
gptkb:Huntington's_Disease_Awareness_Month
|
| gptkbp:advocacy |
gptkb:European_Huntington's_Disease_Network
gptkb:Huntington's_Disease_Society_of_America gptkb:Huntington's_Disease_Association |
| gptkbp:ageLimit |
typically between 30 and 50 years
|
| gptkbp:associatedWith |
anxiety
depression chorea dementia |
| gptkbp:causedBy |
mutation_in_the_HTT_gene
|
| gptkbp:characterDevelopment |
progressive neurodegeneration
|
| gptkbp:community_service |
cognitive assessments
neuroimaging changes |
| gptkbp:demographics |
approximately 5 to 10 per 100,000 people
|
| gptkbp:diseaseResistance |
genetic testing
clinical evaluation |
| gptkbp:geneticDiversity |
HTT
chromosome 4 recommended for at-risk individuals |
| https://www.w3.org/2000/01/rdf-schema#label |
Huntington's disease
|
| gptkbp:impact |
gene therapy
neuroprotective agents nutritional support physical therapy psychotherapy occupational therapy symptomatic treatment affects daily living requires long-term care symptomatic medications |
| gptkbp:introduced |
George_Huntington
|
| gptkbp:localEconomy |
varies by region
affects multiple populations |
| gptkbp:nobleFamily |
autosomal dominant
|
| gptkbp:notableFeature |
gptkb:J._William_Langston
gptkb:Michael_Hayden gptkb:Catherine_H._M._van_der_Meer gptkb:David_H._Gutmann gptkb:Robert_E._H._Smith gptkb:Richard_H._Myers gptkb:David_A._Reiner gptkb:Nancy_Wexler gptkb:Michael_A._McCulloch notable individuals affected Leslie_Thompson H._David_R._H._Smith |
| gptkbp:releaseYear |
1872
|
| gptkbp:research |
ongoing clinical trials
|
| gptkbp:riskManagement |
family history
CAG_repeat_expansion |
| gptkbp:supports |
support groups available
|
| gptkbp:symptoms |
cognitive decline
psychiatric disorders involuntary movements |